Drug intelligence / Profile preview

panitumumab + sotorasib

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Panitumumab + sotorasib is a combination therapy that targets both EGFR and KRAS G12C pathways. Sotorasib is a selective and irreversible KRAS G12C inhibitor that locks the mutant protein in an inactive state, while panitumumab is a monoclonal antibody that binds to EGFR, blocking its activation and downstream signaling. This dual inhibition approach was developed to overcome resistance mechanisms observed with KRAS G12C inhibitor monotherapy in colorectal cancer.

Brand names: Vectibix + Lumakras
Other names: sotorasib plus panitumumabAMG 510 + panitumumab

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on panitumumab + sotorasib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on panitumumab + sotorasib.

Explore the full profile